The obesity drug liraglutide (Novo’s Saxenda) is safe and effective in children aged 6 to 12 years, according to results of the SCALE Kids trial. The results were presented at the annual meeting of the European Association for the Study of Diabetes (EASD) in Madrid this week. The study was…

Eli Lilly’s blockbuster diabetes and obesity drug tirzepatide has achieved good results in a Phase III trial of the medication in adults with heart failure with preserved ejection fraction and obesity. The company announced that the joint glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) agonist met its two primary…

While semaglutide has been in the biopharma limelight for its impressive effects on weight loss in adults with and without type 2 diabetes, it looks like it could soon be playing second fiddle to another glucagon-like peptide 1 GLP-1 receptor agonist-based medication when it comes to weight loss. A study…

Semaglutide, a glucagon-like peptide 1 (GLP-1) receptor agonist designed to treat type 2 diabetes, is also effective at improving cardiovascular and kidney health and reducing the risk for death in people with type 2 diabetes and kidney disease. As reported in the New England Journal of Medicine, the patients randomized…

A new test from Phenomix Sciences can identify responders to semaglutide (Ozempic and Wegovy), according to a study led by Mayo Clinic and presented at Digestive Disease Week 2024—May 18 through May 21. This test answers a key need, as semaglutide is much more effective than previous weight loss drugs.…

Early data suggest Amgen’s experimental weight-loss drug MariTide (maridebart cafraglutide) produces similar effects but is longer-lasting than current market leaders, and blockbusters, glucagon-like peptide-1 inhibitors Novo Nordisk’s Wegovy (semaglutide) and Eli Lilly’s Zepbound (tirzepatide). The study was published in Nature Metabolism this week. The lead authors are Murielle M. Véniant…

Researchers at Case Western Reserve University say that a class of diabetes drugs used to treat type 2 diabetes may reduce the risk of the development of colorectal cancer (CRC). The drugs, called glucagon-like peptide-1 receptor agonists, or GLP-1 RAs are medications that are given by injection to lower blood…

Eli Lilly’s tirzepatide (Mounjaro) led overweight people or people with obesity to lose almost a quarter of their weight in a recent trial that lasted over 72 weeks. Average weight loss was about 60lbs. The drug is a glucose-dependent insulinotropic polypeptide (GIP) receptor and glucagon-like peptide-1 (GLP-1) receptor agonist that…

Topline results from the large-scale Semaglutide Effects on Heart Disease and Stroke in Patients with Overweight or Obesity (SELECT) clinical study released today show that the Novo Nordisk obesity drug reduces the risk of major adverse cardiovascular events by 20 percent. The SELECT trial is the first to demonstrate the…

Researchers based at the Children’s Hospital of Philadelphia (CHOP) have developed and trialed a candidate treatment for children with congenital hyperinsulinism, which was successful at reducing bouts of low blood sugar, or hypoglycemia, in a phase IIa trial. Congenital hyperinsulinism is a rare condition affecting less than 1 in 25,000…